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Antibodies against human papillomavirus (HPV) L1 protein are associated to past infections and related to the 
evolution of the disease, while antibodies against L1 virus like particles (VLPs-L1) are used to follow the 
neutralizing immune response in vaccinated women. In this study, sera antibodies against conformational and 
linear epitopes of L1 protein from HPV16/18 were evaluated to discriminate HPV vaccinated women from those 
naturally infected or with uterine cervical lesions. The VLPs-L1 from HPV16/18 generated in baculovirus were 
purified by CsCl gradient and linear L1 protein obtained by denature VLPs. Serum antibodies against VLPs-L1 
and L1 from vaccinated women or with different exposures to the virus were measured by ELISA. Regresion 
and ROC analysis were carried out to evaluete the test performance to discriminate the different women 
populations. The results showed that antibodies against VLPs-L1-16/18 highly associated with vaccinated 
women (OR=2.11e+08 and 57.74, respectively), but not associations were observed with natural infected 
women or with cervical lesions. However, antibodies against L1-16/18 showed high associations with vaccinated 
women (OR= 101.33 and 37.91, respectively) (p≤ 0.05), but also associations of these antibodies were 
observed with the cervical cancer (CC) group (OR= 3.33 and 5.65, respectively). The ROC analysis showed that 
antibodies against VLPs-L1 and L1 16/18 were highly effective to detect vaccinated women (AUC= 0.96, 0.91. 
0.80 and 0.78, respectively), with high sensitivity for HPV16 (100% and 86.3%), and moderate for HPV18 
(63.6%). However, anti-L1 antibodies had the best test performance to discriminate the cervical intraepithelial 
neoplasia grade 3 (CIN3)/CC group from controls (AUC= 0.67 HPV16 and 0.63 HPV18), with low sensitivity 
(15% to 20%, respectively) and high specificity (96% and 92%, respectively). In conclusion, our results 
suggested that anti-VLPs-L1 16/18 antibodies are highly efficient to detect vaccinated women, but anti-L1 
antibodies are better to discriminate CIN3/CC among the general population. 
 
 
 
 
 
